

# Involvement of autophagy in antibacterial actions of vitamin D in *Helicobacter pylori* infection: abridged secondary publication

W Hu, L Zhang, WKK Wu, CH Cho

## KEY MESSAGES

1. We identified a unique pathogenic mechanism on how *Helicobacter pylori* can survive by hiding inside the autophagosomes in cells.
2. We discovered a novel antibacterial signalling pathway of VD3 through the activation of PDIA3/STAT3 - MCOLN3 - Ca<sup>2+</sup> axis, to reactivate the lysosomal acidification and degradation function of autolysosomes, which is the key signal pathway for the antibacterial action of VD3 both in cells and in animals and perhaps further in humans.

Hong Kong Med J 2020;26(Suppl 4):S26-8

HMRP project number: 13120062

<sup>1</sup> W Hu, <sup>1,2</sup> L Zhang, <sup>1,2</sup> WKK Wu, <sup>3,4</sup> CH Cho

<sup>1</sup> Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong

<sup>2</sup> Institute of Digestive Diseases, State Key Laboratory of Digestive Diseases, LKS Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong

<sup>3</sup> School of Biomedical Science, The Chinese University of Hong Kong, Hong Kong

<sup>4</sup> Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China

\* Principal applicant and corresponding author: chcho@cuhk.edu.hk

*Helicobacter pylori* is a Gram-negative spiral bacterium that has colonised over 50% of the world's population as a result of constant failure in *H pylori* clearance by the host immune system in the upper gastrointestinal tract.<sup>1</sup> Worse, the globally accepted triple therapy (comprising a proton pump inhibitor plus two antibiotics) is challenged by a steady increase in *H pylori* resistance to classical antibiotics, especially to clarithromycin.<sup>2</sup> It has been suggested that the inefficacy in pathogen eradication is due to the capacity of *H pylori* for hiding inside host cells,<sup>3,4</sup> thereby escaping from the innate response by immune cells. Although the precise mechanisms of immune evasion remain obscure, increasing evidence suggests that autophagy plays an important role in the pathogenesis of *H pylori*-associated gastric disorders.<sup>5,6</sup>

Autophagy, characterised by the formation of double-membrane vesicles designated as autophagosomes, is an evolutionarily conserved self-degradation process utilised by host cells to maintain cellular homeostasis and protect against invading pathogens.<sup>7</sup> Lysosomes are membrane-bound organelles that contain over 50 different degradative hydrolases. By fusing with lysosomes, autophagosomes mature into autolysosomes, in which they sequester pathogens followed by degradation by lysosomal proteases.<sup>8</sup> Initially, the autophagic pathway was regarded as the host defence strategy against invading pathogens, as several microbes such as *Listeria monocytogenes* were captured by autophagosomes, and then degraded

to avoid persistent infection.<sup>9</sup> However, emerging evidence underlines an unexpected behaviour of bacteria to disrupt such a defensive autophagic process, allowing active intracellular replication.<sup>10</sup> *H pylori* has been proved to induce autophagy in several gastric cell lines.<sup>11</sup> A suppressive function of *H pylori*-vacuolating cytotoxin in the autophagosome maturation was revealed,<sup>12</sup> suggesting that the bacterium might utilise these intracellular compartments to hibernate and further replicate for a long-term survival in the gastric mucosa. However, the molecular mechanisms by which *H pylori* evades the immune system and the effects of antibiotics need to be elucidated, and novel antibiotics are urgently demanded to efficiently eradicate *H pylori* infection through this unique cellular mechanism. In addition, these agents, if any, could provide a better alternative from the current traditional antibiotics for the treatment of drug-resistant *H pylori*.


In this study, we verified an occurrence of intracellular *H pylori* in normal human gastric epithelial HFE145 cells, and more important, inside the cells of human stomachs. Moreover, we observed that the pathogens were sequestered and survived in non-digestive autophagosomes, which is due to an impaired lysosomal acidification caused by *H pylori* infection. We further showed the involvement of *H pylori* virulence factor CagA in the inhibition of Ca<sup>2+</sup> channel MCOLN3 protein. Thus, our current results might explain the inefficiency in *H pylori* clearance after the treatment with some membrane-impermeable antibiotics. The survival of bacteria in

disarmed autophagosomes might be a significant reason for *H. pylori* to persist and recur in host stomachs.

Vitamin D3 (VD3) as a steroid hormone is known as a supplement to improve overall human health. Emerging evidence points out a potential antimicrobial activity of VD3 in humans. Indeed, its antimicrobial action against *Mycobacterium tuberculosis* infection has been verified,<sup>13</sup> even though the precise mechanisms governing this antibacterial activity remain controversial. In the current study, we reported an unexpected antimicrobial effect of VD3 against *H. pylori* colonisation *in vitro* and in mouse stomachs. In contrast to conventional antimicrobial actions induced by VD3 through the production of antimicrobial peptides such as cathelicidin and  $\beta$ -defensin 2,<sup>14</sup> we proved that such antibacterial effect is mediated through PDIA3 receptor but not the classical vitamin D receptor. We further observed that 1,25D3, the active metabolite of VD3, initiated the nuclear translocation of PDIA3/STAT3 complex, and the subsequent transcriptional up-regulation of MCOLN3 channels. All these play a pivotal role in the antimicrobial action of VD3 against *H. pylori*

infection. MCOLN3 channel is predominantly expressed on the late endosomal and lysosomal membranes (>75%).<sup>15</sup>  $\text{Ca}^{2+}$  release from endolysosome via the MCOLN3 channel is necessary for the lysosomal acidification and maturation.<sup>15,16</sup> Our results showed a modulatory role of PDIA3/STAT3 complex in the MCOLN3 expression. Moreover, VD3 could up-regulate MCOLN3 channel, which is required for  $\text{Ca}^{2+}$  release from lysosomes, and then consequently normalised lysosomal acidification. Finally, the repaired digestive machinery operating inside the gastric cells would drive the bacteria to degradation through the revival autolysosomal pathway.

In conclusion, our study identified a unique pathogenic mechanism on how *H. pylori* can survive by hiding inside the autophagosomes in cells. We discovered a novel antibacterial signalling pathway of VD3 through the activation of PDIA3/STAT3 - MCOLN3 -  $\text{Ca}^{2+}$  axis, to reactivate the lysosomal acidification and degradation function of autolysosomes (Fig), which is the key signal pathway for the antibacterial action of VD3 both in cells and in animals and perhaps further in humans. A



clinical trial in the Prince of Wales Hospital, Hong Kong is currently underway to demonstrate a new therapeutic application of VD3 in *H pylori* infection and gastritis. Understanding of these mechanisms of action may provide new therapeutic strategies and targets and thereby new therapeutic agents for *H pylori* infection and treatment of its associated diseases in the upper gastrointestinal tract.

## Funding

This study was supported by the Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR Government (#13120062). The full report is available from the Health and Medical Research Fund website (<https://rfs1.fhb.gov.hk/index.html>).

## Disclosure

The results of this research have been previously published in:

(1) Hu W, Zhang L, Li MX, et al. Vitamin D3 activates the autolysosomal degradation function against *Helicobacter pylori* through the PDIA3 receptor in gastric epithelial cells. *Autophagy* 2019;15:707-25.

## References

1. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 2008;372:392-7.
2. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. *Aliment Pharmacol Ther* 2016;43:514-33.
3. Allen LA, Schlesinger LS, Kang B. Virulent strains of *Helicobacter pylori* demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages. *J Exp Med* 2000;191:115-28.
4. Deen NS, Huang SJ, Gong L, Kwok T, Devenish RJ. The impact of autophagic processes on the intracellular fate of *Helicobacter pylori*: more tricks from an enigmatic pathogen? *Autophagy* 2013; 9:639-52.
5. Chu YT, Wang YH, Wu JJ, Lei HY. Invasion and multiplication of *Helicobacter pylori* in gastric epithelial cells and implications for antibiotic resistance. *Infect Immun* 2010;78:4157-65.
6. Wang YH, Gorvel JP, Chu YT, Wu JJ, Lei HY. *Helicobacter pylori* impairs murine dendritic cell responses to infection. *PLoS One* 2010;5:e10844.
7. Klionsky D, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012;8:445-544.
8. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. *Annu Rev Genet* 2009;43:67-93.
9. Rich KA, Burkett C, Webster P. Cytoplasmic bacteria can be targets for autophagy. *Cell Microbiol* 2003;5:455-68.
10. Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. *Cell* 2005;120:159-62.
11. Terebiznik MR, Raju D, Vázquez CL, et al. Effect of *Helicobacter pylori*'s vacuolating cytotoxin on the autophagy pathway in gastric epithelial cells. *Autophagy* 2009;5:370-9.
12. Raju D, Hussey S, Ang M, et al. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote *Helicobacter pylori* infection in humans. *Gastroenterology* 2012;142:1160-71.
13. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus type 1 and *Mycobacterium tuberculosis* infection in macrophages through the induction of autophagy. *PLoS Pathog* 2012;8:e1002689.
14. Youssef DA, Miller CW, El-Abbassi AM, et al. Antimicrobial implications of vitamin D. *Dermatoendocrinol* 2011;3:220-9.
15. Zeevi DA, Frumkin A, Bach G. TRPML and lysosomal function. *Biochim Biophys Acta* 2007;1772:851-8.
16. Di Palma F, Belyantseva IA, Kim HJ, Vogt TF, Kachar B, Noben-Trauth K. Mutations in *Mcoln3* associated with deafness and pigmentation defects in varitint-waddler (Va) mice. *Proc Natl Acad Sci U S A* 2002;99:14994-9.